The Herald Business Journal Staff

BOTHELL — Juno Therapeutics announced on Monday that it had entered into a lease agreement for a facility in Bothell to manufacture the company’s cell therapy products.

The Seattle company expects to move into the 67,799-square-foot building once the previous tenant leaves. The company did not give an address for their new building. It also did not say how many people will be employed at the site.

The facility is expected to come online in early 2016 and support Juno’s planned multicenter clinical trial, additional clinical programs in Juno’s pipeline and the company’s first commercial products.

Juno Therapeutics CEO and president Hans Bishop said in a statement the manufacturing facility is an important milestone for the company.

The biopharmaceutical company is focused on using medicine to re-engage the body’s immune system to treat cancer. The company aims to genetically engineer T cells to recognize and kill cancer. Juno Therapeutics says several potential products have shown evidence in clinical trials to shrink leukemia and lymphoma.

Gov. Jay Inslee said in a statement released from the company that he’s thrilled Juno Therapeutics is “part of our life science ecosystem.”

“The expansion of Juno Therapeutics’ manufacturing presence in Washington state will increase Juno’s ability to provide their potentially lifesaving treatments to more patients across the country and will produce high wage jobs in the region,” Inslee said.